相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Similarities and differences between axial spondyloarthritis and axial psoriatic arthritis
Weijie Wang et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials
Arthur Kavanaugh et al.
ADVANCES IN THERAPY (2023)
Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms
Denis Poddubnyy
DRUGS (2023)
Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Ying-Ying Leung et al.
JOURNAL OF RHEUMATOLOGY (2023)
MRI Findings in Axial Psoriatic Spondylarthritis
Loredana Sabina Pascu et al.
DIAGNOSTICS (2023)
Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
Anne Constanze Regierer et al.
RMD OPEN (2023)
Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry
Adrian Ciurea et al.
RMD OPEN (2023)
Same, same or different? Commonalities and differences between spondyloarthritis and its subsets of axial and peripheral spondyloarthritis with psoriatic arthritis and its diverse phenotypes
Fabian Proft et al.
RMD OPEN (2023)
Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (Be-)GIANT multicentre cohorts
Manouk de Hooge et al.
RMD OPEN (2023)
No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
Juergen Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
Laura C. Coates et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
Andrew Ostor et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Psoriatic Spondylitis: A Disease Manifestation in Debate Evidences to Know for the Clinical Rheumatologist
Henning K. Zeidler
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2022)
Characterising axial psoriatic arthritis: correlation between whole spine MRI abnormalities and clinical, laboratory and radiographic findings
Pamela Diaz et al.
RMD OPEN (2022)
Axial psoriatic arthritis: New entity or clinical form only?
Daniel Wendling et al.
JOINT BONE SPINE (2022)
Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis
Timothy S. H. Kwok et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?
Fabiola Atzeni et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry
Xabier Michelena et al.
RMD OPEN (2022)
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
Philip J. Mease et al.
RHEUMATOLOGY AND THERAPY (2022)
Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Dafna D. Gladman et al.
TRIALS (2022)
Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy
Hyoun-Ah Kim et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2022)
Efficacy and Safety of Guselkumab, an Interleukin-23p 19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis
Iain B. McInnes et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
Xenofon Baraliakos et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
IL-23 and axial disease: do they come together?
Philip Mease et al.
RHEUMATOLOGY (2021)
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
Dennis McGonagle et al.
RHEUMATOLOGY (2021)
Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study
D. Benavent et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)
Axial Psoriatic Arthritis
Dafna D. Gladman
CURRENT RHEUMATOLOGY REPORTS (2021)
Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis
Dennis McGonagle et al.
FRONTIERS IN IMMUNOLOGY (2021)
Axial involvement in psoriatic arthritis: An update for rheumatologists
Denis Poddubnyy et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)
Axial Psoriatic Arthritis A Distinct Clinical Entity in Search of a Definition
Xabier Michelena et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2020)
The many faces of psoriatic arthritis: their genetic determinism
Robert Winchester et al.
RHEUMATOLOGY (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Axial spondyloarthritis: coming of age
Helena Marzo-Ortega
RHEUMATOLOGY (2020)
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
Philip S. Helliwell et al.
RMD OPEN (2020)
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
Dennis G. McGonagle et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different?
Vinod Chandran
CURRENT OPINION IN RHEUMATOLOGY (2019)
Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression
Richard James Cuthbert et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease et al.
JOURNAL OF RHEUMATOLOGY (2018)
Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison
Joy Feld et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis
Eric Gracey et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Interleukin-23-Dependent/T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice
Annika Reinhardt et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells
Peggy Jacques et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells
Jonathan P. Sherlock et al.
NATURE MEDICINE (2012)
Imaging the spine in arthritis-a pictorial review
Anne Grethe Jurik
INSIGHTS INTO IMAGING (2011)
Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis
Vinod Chandran et al.
JOURNAL OF RHEUMATOLOGY (2010)
Validity of the Bath Ankylosing Spondylitis Disease Activity Index for the Evaluation of Disease Activity in Axial Psoriatic Arthritis
Jose Luis Fernandez-Sueiro et al.
ARTHRITIS CARE & RESEARCH (2010)
Axial Psoriatic Arthritis: Update on a Longterm Prospective Study
Vinod Chandran et al.
JOURNAL OF RHEUMATOLOGY (2009)
Psoriatic arthritis and rheumatoid arthritis: Findings in contrast-enhanced MRI
Helmut Schoelinast et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2006)